424 results on '"Frelinger, Andrew L."'
Search Results
2. Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome
3. Clinical Cytometry for Platelets and Platelet Disorders
4. Inhibition of transcription factor NFAT activity in activated platelets enhances their aggregation and exacerbates gram-negative bacterial septicemia
5. Sex-specific platelet activation through protease-activated receptor-1 in patients undergoing cardiac catheterization
6. Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers
7. Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC
8. Dysregulation of platelet serotonin, 14–3–3, and GPIX in sudden infant death syndrome
9. Platelet Physiology
10. Using extracellular calcium concentration and electric pulse conditions to tune platelet-rich plasma growth factor release and clotting
11. Novel aspects of antiplatelet therapy in cardiovascular disease
12. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease
13. High serum serotonin in sudden infant death syndrome
14. OMIP‐097: High‐parameter phenotyping of human platelets by spectral flow cytometry
15. Calpain-1 regulates platelet function in a humanized mouse model of sickle cell disease
16. New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors
17. Platelet Function Testing in Clinical Research Trials
18. Contributors
19. Flow Cytometry
20. Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia
21. Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP
22. Platelet Phenotyping by Full Spectrum Flow Cytometry
23. A phase 1 study of prasugrel in patients with sickle cell disease: Effects on biomarkers of platelet activation and coagulation
24. Expert opinion on the use of platelet secretion assay for the diagnosis of inherited platelet function disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology
25. The aryl hydrocarbon receptor directs hematopoietic progenitor cell expansion and differentiation
26. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation
27. Platelet Physiology
28. Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y 1, P2Y 12 and P2X 1 receptors
29. Comprehensive phenotyping of human platelets by single‐cell cytometry
30. Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology
31. Decreased platelet surface phosphatidylserine predicts increased bleeding in patients with severe factor VIII deficiency
32. A $\beta_3$ Integrin Mutation Abolishes Ligand Binding and Alters Divalent Cation-Dependent Conformation
33. Immunophenotypic Analysis of Platelets by Flow Cytometry
34. Protocol for assessing and visualizing cell microaggregate formation in whole blood by imaging flow cytometry
35. Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology
36. Platelet Immunophenotyping by High‐Dimensional Mass Cytometry
37. The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology
38. Activation of platelet-rich plasma by pulse electric fields: Voltage, pulse width and calcium concentration can be used to control and tune the release of growth factors, serotonin and hemoglobin
39. List of Contributors
40. Clinical and Laboratory Significance of Defective P2Y12 Pathway Function in Patients with Myeloproliferative Neoplasms: A Pilot Study
41. A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity
42. Current Options in Platelet Function Testing
43. Platelet mass cytometry: Optimization of sample, reagent, and analysis parameters
44. Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease
45. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial
46. Platelet surface GPIbα, activated GPIIb-IIIa, and P-selectin levels in adult veno-arterial extracorporeal membrane oxygenation patients
47. Platelet count and disease – editorial policy
48. Biomarkers of platelet activation and cardiovascular risk in the DAPT trial
49. Platelet activation in cystic fibrosis
50. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.